BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 908140)

  • 1. The urinary excretion of the nucleosides pseudouridine and 1-methylinosine during normal menstrual cycle.
    Lehtiö H; Mäenpää PH
    Clin Chim Acta; 1977 Oct; 80(1):181-5. PubMed ID: 908140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The urinary excretion of nucleosides of ribonucleic acid by patients with advanced cancer.
    Waalkes TP; Gehrke CW; Zumwalt RW; Chang SY; Lakings DB; Tormey DC; Ahmann DL; Moertel CG
    Cancer; 1975 Aug; 36(2):390-8. PubMed ID: 1157009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary excretion by cancer patients of the nucleosides N-dimethylguanosine, 1-methylinosine, and pseudouridine.
    Waalkes TP; Dinsmore SR; Mrochek JE
    J Natl Cancer Inst; 1973 Jul; 51(1):271-4. PubMed ID: 4720877
    [No Abstract]   [Full Text] [Related]  

  • 4. Biological markers in breast carcinoma--clinical correlations with pseudouridine, N2,N2-dimethylguanosine, and 1-methylinosine.
    Tormey DC; Waalkes TP; Gehrke CW
    J Surg Oncol; 1980; 14(3):267-73. PubMed ID: 7392649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative determination of methylated nucleosides and pseudouridine in urine by gas-liquid chromatography.
    Chang SY; Lakings DB; Zumwalt RW; Gehrke CW; Waalkes TP
    J Lab Clin Med; 1974 May; 83(5):816-30. PubMed ID: 4821860
    [No Abstract]   [Full Text] [Related]  

  • 6. Relationship of urinary excretion of modified nucleosides to disease status in childhood acute lymphoblastic leukemia.
    Heldman DA; Grever MR; Miser JS; Trewyn RW
    J Natl Cancer Inst; 1983 Aug; 71(2):269-73. PubMed ID: 6576186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary excretion of modified nucleosides in chronic myelogenous leukemia.
    Heldman DA; Grever MR; Speicher CE; Trewyn RW
    J Lab Clin Med; 1983 May; 101(5):783-92. PubMed ID: 6572681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between urinary excretion of modified nucleosides and rheumatoid arthritis process.
    Tebib JG; Reynaud C; Cedoz JP; Letroublon MC; Niveleau A
    Br J Rheumatol; 1997 Sep; 36(9):990-5. PubMed ID: 9376997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A quantitative approach to determining disease response during therapy using multiple biologic markers: application to carcinoma of the breast.
    Woo KB; Waalkes TP; Ahmann DL; Tormey DC; Gehrke CW; Oliverio VT
    Cancer; 1978 May; 41(5):1685-703. PubMed ID: 348295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations of pseudouridine in 8-hour and 24-hour urinary samples determined by high-performance liquid chromatography.
    Sjølin KE
    Urol Res; 1982; 10(5):245-8. PubMed ID: 7164220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleoside excretion in breast cancer: comparison with other biochemical tumour-index-substances.
    Coombes RC; Powles TJ; Gehrke CW; Waalkes TP; Neville AM
    Invest Cell Pathol; 1979; 2(1):11-4. PubMed ID: 511604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudouridine: a modified nucleoside as biological marker in malignant lymphomas.
    Rasmuson T; Björk GR
    Cancer Detect Prev; 1983; 6(1-2):293-6. PubMed ID: 6883387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age dependence of human urinary pseudouridine excretion.
    Tritsch GL; Luch JM; Evans JT; Mittelman A
    Biochem Med; 1979 Dec; 22(3):387-90. PubMed ID: 533544
    [No Abstract]   [Full Text] [Related]  

  • 14. Pyrimidine nucleoside, pseudouridine, and modified nucleoside excretion by growing and resting fibroblasts.
    Uziel M; Selkirk JK
    J Cell Physiol; 1979 May; 99(2):217-22. PubMed ID: 457787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary excretion of pseudouridine in patients with hepatocellular carcinoma.
    Tamura S; Amuro Y; Nakano T; Fujii J; Moriwaki Y; Yamamoto T; Hada T; Higashino K
    Cancer; 1986 Apr; 57(8):1571-5. PubMed ID: 2418945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary modified nucleosides as tumor markers in cancer of the urinary organs or female genital tract.
    Koshida K; Harmenberg J; Stendahl U; Wahren B; Borgström E; Helström L; Andersson L
    Urol Res; 1985; 13(5):213-8. PubMed ID: 4060364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary excretion of purines, purine nucleosides, and pseudouridine in immunodeficient children.
    Mills GC; Schmalstieg FC; Koolkin RJ; Goldblum RM
    Biochem Med; 1982 Feb; 27(1):37-45. PubMed ID: 7115356
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantitation of urinary nucleosides by high-performance liquid chromatography.
    Liebich HM; Di Stefano C; Wixforth A; Schmid HR
    J Chromatogr A; 1997 Feb; 763(1-2):193-7. PubMed ID: 9129323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary excretion of purines, purine nucleosides, and pseudouridine in adenosine deaminase deficiency.
    Mills GC; Goldblum RM; Newkirk KE; Schmalstieg FC
    Biochem Med; 1978 Oct; 20(2):180-99. PubMed ID: 736910
    [No Abstract]   [Full Text] [Related]  

  • 20. [Interrelationship of pseudouridine and transfer RNA metabolic disorders in thermal injury].
    Salomatin VV; Efimenko GP; Kamilov FKh; Lifshits RI
    Vopr Med Khim; 1977; 23(5):642-6. PubMed ID: 595499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.